How should I transition a patient from propylthiouracil to methimazole, and what are the reasons for making this switch?

Transitioning from PTU to Methimazole

Switch from PTU to methimazole using a dose conversion ratio of 20-30:1 (e.g., 300 mg PTU = 10-15 mg methimazole), check thyroid function 2 weeks after switching, then every 2-4 weeks until stable. 1, 2

Why Make This Switch?

The primary reason to transition from PTU to methimazole is safety. PTU carries a risk of potentially fatal hepatotoxicity that can occur rapidly and unpredictably, with cases of liver failure, liver transplantation, and death reported in both adults and children 3. This hepatotoxicity is particularly concerning because:

• Biochemical monitoring of liver function does not reliably prevent severe liver injury due to its rapid and unpredictable onset 3
• The risk appears to increase with prolonged use 1
• Maternal hepatotoxicity during pregnancy poses risks to both mother and fetus 1

Methimazole is the preferred antithyroid drug in virtually all non-pregnant patients 1, with advantages including:

• Once-daily dosing (better adherence)
• Lower risk of major side effects compared to PTU
• No association with ANCA-positive vasculitis (which PTU can cause) 1
• Lower risk of agranulocytosis at maintenance doses 1

How to Perform the Transition

Dose Conversion

Use a potency ratio of 20-30:1 when converting 1:

• 300 mg PTU daily → 10-15 mg methimazole daily
• 200 mg PTU daily → 7-10 mg methimazole daily
• 100 mg PTU daily → 3-5 mg methimazole daily

Monitoring Protocol

1. Check thyroid function 2 weeks after switching 2
2. Recheck every 2-4 weeks until stable 2
3. Monitor for symptoms of agranulocytosis (fever, sore throat) or hepatic injury (jaundice, right upper quadrant pain, fatigue) 1

Target Thyroid Levels

• Maintain free T4 at or slightly above the upper limit of normal range
• TSH may remain suppressed initially and should be interpreted cautiously in conjunction with free T4 and T3 1

Special Populations

Pregnancy Context

If the patient is pregnant or planning pregnancy, the timing matters critically:

• First trimester: PTU is preferred due to methimazole's association with rare congenital anomalies (aplasia cutis, choanal/esophageal atresia) 1, 4
• Second and third trimesters: Switch to methimazole to avoid PTU hepatotoxicity risk 1, 2
• Postpartum/nursing: Methimazole is strongly preferred over PTU 1

Non-Pregnancy Situations

Switch immediately unless:

• Patient is in first trimester of pregnancy
• Patient has thyroid storm (PTU may be preferred for its additional peripheral T4 to T3 conversion blocking effect, though recent evidence questions this) 1, 5
• Patient had a severe reaction to methimazole and refuses radioactive iodine or surgery 1

Common Pitfalls to Avoid

1. Don't use equivalent dosing of 1:10 or 1:15 - this underestimates methimazole potency. Use 20-30:1 ratio 1

2. Don't delay monitoring - check thyroid function at 2 weeks, not 4-6 weeks, as pharmacokinetic differences between drugs can lead to poor control 1, 2

3. Don't continue PTU long-term without compelling reason - the hepatotoxicity risk and need for multiple daily doses make it inferior to methimazole for chronic management 1, 3

4. Don't assume cross-reactivity won't occur - while rare, patients with allergic reactions to one drug may react to the other, though successful re-challenge with lower methimazole doses has been reported 6, 7

5. Don't forget to counsel patients - inform them to immediately report fever, sore throat, jaundice, or abdominal pain and to stop the medication if these occur 1

Patient Counseling Points

Before switching, inform patients about:

• The reason for the switch (safety profile favoring methimazole)
• Signs of agranulocytosis: fever, sore throat, mouth sores
• Signs of hepatotoxicity: jaundice, dark urine, pale stools, right upper quadrant pain
• The need for close monitoring during the transition period
• Instruction to stop medication immediately and contact physician if warning symptoms develop 1